OptiBiotix adds further level of protection with new patent filings

OptiBiotix adds further level of protection with new patent filings

OptiBiotix Health plc (LON:OPTI) has announced the filing of two new patents covering its cholesterol reducing product. This increases the number of patents from nine to eleven.

The new patents reflect:-
· The success of its human studies designed to establish safety and efficacy on its capsular food supplement to reduce cholesterol
· The success of manufacturing studies designed to identify maximum production yields and volumes on its cholesterol reducing strain
· The identification of additional health benefits (hypertension reduction) shown by its cholesterol reducing strain

Stephen O’Hara, CEO of OptiBiotix, commented: “We are pleased to announce the filing of these patents which add a further level of protection and value to our cholesterol reducing product. We believe these patents will further enhance the value proposition and negotiating position with commercial partners and make a significant contribution to building a successful and sustainable business for shareholders.”

See article in full at DirectorsTalkInterviews.com

Important information

This information is of a general nature and does not constitute an offer to provide services.

The opinions and conclusions given here are those of Seneca Partners and are subject to change without notice.

The value of investments and/or any income arising from them may fluctuate.

Past performance is not necessarily a guide to future performance.

Important notice

The products and services shown on this website place capital at risk. Investors may receive less in returns than they have invested. Investments may not allow for capital to be withdrawn on demand. If an investment provides tax relief then this relief is subject to change and is dependant on personal circumstances. Any reference to past performance or forecasted performance is not a reliable indicator of future performance.

Seneca Partners recommends that any investor seeks specialised financial and/or tax advice before investing. Seneca Partners does not provide advice and the information on this website, including but not limited to news, should not be construed as such.

Please confirm that you understand this warning and wish to proceed.